Last reviewed · How we verify
Allogeneic transfusion
Allogeneic transfusion involves the transfer of blood components from a donor to a recipient to replace or supplement the recipient's blood supply.
Allogeneic transfusion involves the transfer of blood components from a donor to a recipient to replace or supplement the recipient's blood supply. Used for Treatment of anemia in patients with chronic kidney disease, Treatment of bleeding disorders, such as hemophilia A and B.
At a glance
| Generic name | Allogeneic transfusion |
|---|---|
| Sponsor | Helios Klinik Gotha/Ohrdruf |
| Modality | Biologic |
| Therapeutic area | Oncology, Hematology |
| Phase | Phase 2 |
Mechanism of action
This process can help increase red blood cell count, improve oxygen delivery to tissues, and support the recipient's overall health. Allogeneic transfusion can be used to treat a variety of conditions, including anemia, bleeding disorders, and blood cancers.
Approved indications
- Treatment of anemia in patients with chronic kidney disease
- Treatment of bleeding disorders, such as hemophilia A and B
Common side effects
- Acute hemolysis
- Graft-versus-host disease
- Transfusion-related acute lung injury
Key clinical trials
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) (PHASE2)
- Romiplostim N01 for Platelet Recovery After Haploidentical HSCT (PHASE1)
- Delayed Cold-Stored Platelets -PLTS-1 (PHASE2)
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogeneic transfusion CI brief — competitive landscape report
- Allogeneic transfusion updates RSS · CI watch RSS
- Helios Klinik Gotha/Ohrdruf portfolio CI